Silobreaker.com    Log In
   My Page    Help   
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Sunday, November 22, 2009 12:34 AM

ZymoGenetics Incorporated

Type: Company
Name: ZymoGenetics Incorporated
First Reported 11/20/2009 - Updated 11/20/2009 - 1 Documents
Will ZymoGenetics shares start to bleed?
By Anand Basu BANGALORE (Reuters) - Shares of ZymoGenetics Inc (ZGEN.O ) have gained 37 percent in the last six months, as its synthetic blood-clotting enzyme Recothrom continues to gain market share. However, in the last three months a slew of bad ... [Economy-Finance - 11/20/2009]
First Reported 11/18/2009 - Updated 11/18/2009 - 1 Documents
New York Stock Exchange - Click to view 360-page
New York Stock Exchange
The Best Opportunity This Decade
Well, we're probably on our way out of the recession, even though it doesn't feel like it yet. Just remember: the end of a recession, by definition, is always at the bottom, when things feel the worst.That will have made 11 recessions over the past 60 ... [Motley Fool - 11/18/2009]
First Reported 11/19/2009 - Updated 11/19/2009 - 1 Documents
Will ZymoGenetics shares start to bleed?
BANGALORE (Reuters) - Shares of ZymoGenetics Inc have gained 37 percent in the last six months, as its synthetic blood-clotting enzyme Recothrom continues to gain market share. ... [Reuters: Deals - 11/19/2009]
First Reported 10/27/2009 - Updated 10/27/2009 - 3 Documents
Phase 2 clinical study of PEG-Interferon lambda commenced
ZymoGenetics, Inc. (NASDAQ: ZGEN) today announced the initiation of a Phase 2 clinical trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection (the “EMERGE” study). The first patient ... [News-Medical.Net - 10/27/2009]
First Reported 11/04/2009 - Updated 11/05/2009 - 2 Documents
King Pharmaceuticals Inc - Click to view 360-page
King Pharmaceuticals Inc
3 restraining orders placed on ZymoGenetics regarding Recothrom
A federal court in Tennessee granted three temporary restraining orders against ZymoGenetics, preventing it from marketing Recothrom, a drug used to control hemorrhage. The orders came after King Pharmaceuticals and three other firms filed a lawsuit accusing ... [SmartBrief - 11/05/2009]
First Reported 10/31/2009 - Updated 10/31/2009 - 3 Documents (in Health)
Bristol-Myers Squibb Company - Click to view image in its original context
Bristol-Myers Squibb Company
Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda...
BusinessWire - --Results support moving to dose-ranging Phase II studies in treatment-naive HCV patientsBristol-Myers Squibb Company (NYSE: BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) today presented final results from a Phase 1b clinical trial of PEG-Interferon ... [Forbes.com - 10/31/2009]
First Reported 10/29/2009 - Updated 10/30/2009 - 2 Documents (in Corporate Deals)
Microsoft Corporation - Click to view image in its original context
Microsoft Corporation
ZymoGenetics Rival Emerges, Omeros IPO Casts Shadow, Microsofts HealthVault Seeks Users, & More Seattle Area Life Sciences News
We had a little something for everybody on the life sciences beat this week, with news on biopharmaceuticals, devices, and healthcare software. Seattle-based Omeros (NASDAQ: OMER) had potential to be a bellwether for the U.S. biotech sector earlier this ... [Xconomy - 10/30/2009]
First Reported 11/02/2009 - Updated 11/02/2009 - 3 Documents (in Medicine)
BMY and ZGen present Phase 1B results for PEG-Interferon lambda in HCV patients
Bristol-Myers Squibb Company (NYSE: BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) p ... [News-Medical.Net - 11/02/2009]
First Reported 11/04/2009 - Updated 11/04/2009 - 2 Documents
STOCKS NEWS US-Lazard downgrades eight retailers
Stocks on the moveReal-time Equity newsU.S. stock market report0859 EST 04Nov2009-Lazard downgrades eight retailers Lazard Capital Markets on Wednesday downgraded eight U.S. retailers, citingthe group's outperformance since March.The retail, apparel and ... [FinanzNachrichten.de - 11/04/2009]
First Reported 10/27/2009 - Updated 10/28/2009 - 2 Documents (in Health)
ZGEN: To Receive $70M Milestone from Initiation of Phase 2 Hepatitis C Trial
ZymoGenetics, Inc. (ZGEN) announced the initiation of a Phase 2 clinical trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV) infection. The first patient has been dosed in the study, triggering ... [Individual.com - 10/28/2009]
First Reported 11/04/2009 - Updated 11/04/2009 - 2 Documents
BRIEF-Zymogenetics says King Pharma filed suit against co
Nov 4 (Reuters) - Zymogenetics Inc: * Says SEC filing* Says King alleges co has engaged in unfair competition, false advertising,trademark infringement* Says disputes allegations of wrongdoing in King's complaint* Currently sees no adverse material ... [Forbes.com - 11/04/2009]
First Reported 10/28/2009 - Updated 10/28/2009 - 1 Documents (in Medicine)
ZymoGenetics to Webcast Presentation at Oppenheimer Healthcare
ZymoGenetics, Inc. ZGEN announced today that Stephen W. Zaruby, President of ZymoGenetics, will provide an update on company activities at the Oppenheimer 20th Annual Healthcare Conference in New York City on Wednesday, November 4, 2009 at 10:50 a.m. ... [Business Wire via MSN Money - 10/28/2009]

Quotes

In the report, the analyst notes: "The Company's first internally developed product candidate, RECOTHROM(R) Thrombin, was approved by the U S FoodFood and Drug Administration in January 2008 for use as a topical hemostat to control moderate bleeding during surgical procedures and is now being marketed in the United States. Simultaneously, ZGEN entered into a co-promotion agreement with Bayer Healthcare LLC under which Bayer is assisting the Company with the promotion of RECOTHROM in the U S for up to four years, ending in March 2012. 'At the beginning of 2009, ZGEN and Bristol-Myers Squibb Company announced a global collaboration for PEG-Interferon lambda, a novel type 3 interferon for the treatment of Hepatitis C, and its related development program. Under the terms of the collaboration, Bristol-Myers Squibb agreed to pay ZymoGenetics an upfront cash payment of $85 million for the development and commercialization rights to PEG-Interferon lambda, and to pay an additional license fee of $20 million in 2009.' To read the entire report visit: http://www.stockpreacher.com/n/ZGEN"
Trading Outlook for ZymoGenetics Inc. Issued by StockPreacher.com [GlobeNewswire via MSN Money - 11/12/2009]
"With greater than $50 million in anticipated 2010 sales, Recothrom has achieved a level of sales which makes the asset far more attractive to either ZymoGenetics or another party" Wedbush Pacgrow Lifesciences analyst Gregory Wade said
ZymoGenetics shares rise on narrower Q3 loss, strong revenue [FinanzNachrichten.de - 11/06/2009]
...company is making important strides, both financially and operationally," said Douglas E Williams, Ph D , Chief Executive Officer of ZymoGenetics. "RECOTHROM sales trends continue to improve. We presented final Phase 1b clinical trial results for PEG-Interferon lambda with positive results for tolerability and antiviral activity, and the Phase 2 clinical trial is underway, triggering a $70.0 million milestone payment from our partner Bristol-Myers Squibb."
ZymoGenetics Reports Third Quarter 2009 Financial Results [Forbes.com - 11/05/2009]

More Content

All (85) | News (81) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (1)
sort by: Date | Relevance
Notable 52-Week NYSE New Highs and Lows 11/19: ... [Street Insider - 11/19/2009]
BUY OR SELL-Will ZymoGenetics shares start to b... [Interactive Investor International - 11/19/2009]
Will ZymoGenetics shares start to bleed? [Reuters: Deals - 11/19/2009]
The Best Opportunity This Decade [Motley Fool - 11/18/2009]
The Icos Alumni: Where Are They Now? [Xconomy - 11/18/2009]
Research and Markets: Dealmaking and Industry O... [RBC Dain Rauscher - 11/17/2009]
Trading Outlook for ZymoGenetics Inc. Issued by... [GlobeNewswire via MSN Money - 11/12/2009]
Alder’s Breakout $1B Deal, Kineta Teams With UW... [Xconomy - 11/12/2009]
SEC, Merriman execs settle over Del Biaggio case [San Jose Business Journal - 11/10/2009]
Alder Scores Deal With Bristol-Myers Potentiall... [Xconomy - 11/10/2009]
Judge removes 3 restraining orders against Zymo... [SmartBrief - 11/09/2009]
ZymoGenetics says restraining orders lifted [Biz Journals - 11/06/2009]
BUYINS.NET: ZymoGenetics (ZGEN) Up After BUYINS... [Individual.com - 11/06/2009]
Drug stocks edge higher; Alkermes slides [MarketWatch - 11/06/2009]
Tenaris Net Falls 60%; Magna Intl Sales Down [123Jump - 11/06/2009]
ZymoGenetics Inc. Is Climbing Following Q3 Report [RTTNews.com - 11/06/2009]
Morning Movers 11/06: ACLS, CVM, ZIOP, LPSN, CA... [Street Insider - 11/06/2009]
ZymoGenetics shares rise on narrower Q3 loss, s... [FinanzNachrichten.de - 11/06/2009]
Pegylated Interferon Lambda Demonstrates Good A... [HIV and Hepatitis.com - 11/06/2009]
Drug stocks mixed; Alkermes slides [MarketWatch - 11/06/2009]
Wedbush Upgrades ZymoGenetics (ZGEN) to Outperf... [Street Insider - 11/06/2009]
Tenaris Net Falls 60%; Magna International Sale... [123Jump - 11/06/2009]
ZymoGenetics narrows loss, revenue up [Biz Journals - 11/05/2009]
ZymoGenetics Reports Third Quarter 2009 Financi... [Forbes.com - 11/05/2009]
ZymoGenetics Q3 09 Earnings Conference Call At ... [RTTNews.com - 11/05/2009]
3 restraining orders placed on ZymoGenetics reg... [SmartBrief - 11/05/2009]
Fed Slows Momentum for Most ETFs (Daily ETF Wra... [Smart Money - 11/04/2009]
Trading Radar for 11/05: Starbucks (SBUX), CBS ... [Street Insider - 11/04/2009]
ZymoGenetics hit with restraining orders [Biz Journals - 11/04/2009]
STOCKS NEWS US-Lazard downgrades eight retailers [FinanzNachrichten.de - 11/04/2009]
1 2 3
In Focus
  •  
PHASE 2, Luke Timmerman, Brian Abrahams, [more]
  •  
Bristol-Myers Squibb Company, King Pharmaceuticals Inc, Alkermes Inc, [more]
  •  
Food and Drug Administration, US Securities and Exchange Commission, American Association for the Study of ..., [more]
  •  
Interferon, Hepatitis C, ribavirin, [more]
  •  
Seattle, Boston (Massachusetts, United States), Bangalore, [more]
  •  
United States, Netherlands, Denmark, [more]
  •  
Medicine, Medication, Biology, [more]
  •  
Pharma & Biotech, IT, Health, [more]
Business Wire via MSN Money, Biz Journals, Forbes.com, [more]
Content Volume
Network
Trends

Blogs

sort by: Date | Relevance
Will ZymoGenetics shares start to bleed? [Economy-Finance - 11/20/2009]
By Anand Basu BANGALORE (Reuters) - Shares of ZymoGenetics Inc (ZGEN.O ) have gained 37 percent in the last six months, as its synthetic blood-clotting enzyme ...
ZymoGenetics, Inc., Q1 2009 Earnings Call Trans... [Biotech Sector and Stocks Analysis from Seeking ... - 05/06/2009]
ZymoGenetics, Inc., (ZGEN) Q1 2009 Earnings Call May 5, 2009 4:30 pm ETComplete Story » ...
Q1 2009 Biotech Roundup: The Good, the Bad and ... [Biotech Sector and Stocks Analysis from Seeking ... - 04/02/2009]
Mark Cifra submits:Now that the first quarter of 2009 has ended, I took a look back at some of the news that moved the stocks in the sector, and as usual with the ...
1

  •  
  •  
  •